Study startup

From final protocol to first-patient-in.

One partner for site selection, feasibility, contracts, approvals and site initiation, in every country. Your team keeps every decision and every signature.

Plan your study startup See the method
01 · Ryght
Site ID and feasibility
Ranked list in under 24 hours
02 · Ryght
PI says yes
The startup clock starts
03 · Ryght
Activation
Contracts, approvals, supply
04 · Ryght
Site screening
Green light and SIV
05 · Your partner
Study conduct
Your CRO or conduct partner
Why the months go missing

Regulators are predictable. Contracts are not.

Every regulator runs on a published clock, so each region falls in a narrow band. Site contracts run longer and vary far more. That is where Ryght compresses the timeline.

0
8
16
24
32
40 wks
US, Canada, Australia
 
0 to 8
United Kingdom
 
6 to 10
Japan
 
8 to 12
China
 
13 to 19
European Union, one CTIS filing
 
15 to 20
Latin America
 
10 to 26
Site contracts
 
 
 Regulatory review
 Budget and CTA, 6 to 24 weeks
 Can stretch to 40 weeks
Modeled planning weeks from submission to approval, by region. Drawn from the 30-country Ryght Phase 3 model. Ryght research, September 2026.
The activation method

Thirteen steps. Three stages. The same motion in every country.

 Ryght runs today
 Run with in-country partners
 AI-addressable (every step)
A · Select and confirm
01Site identification
02Feasibility
03CDA and NDA execution
04Site confirmation
B · Contract and approve
05Budget and CTA negotiation
06Insurance and indemnity
07Informed consent
08Regulatory documents
09IRB and ethics approval
10Health authority filings
C · Supply and go
11Import and export permits
12Drug supply and central lab
13Site initiation visit
Every activation produces the same six artifacts
Country Activation Brief
Site Activation Tracker
Regulatory and ethics submission package
CTA and budget pack
Essential document binder (eTMF)
Green-light checklist
Startup timelines

Three months sooner to 75% of sites active.

Global Phase 3 oncology
Modeled
30 countries, about 200 sites and 600 patients
First patient in
 
Week 20
 
Week 26
75% of sites active
 
Week 34
 
Week 48
Phase 2 oncology, US and Australia
Modeled
About 20 sites and 100 patients
First patient in
 
Week 15
 
Week 20
75% of sites active
 
Week 22
 
Week 34
 With Ryght
 Industry baseline
Weeks from final protocol. Modeled from mechanisms and includes roadmap capabilities.
What Ryght does differently

Data picks the sites. Templates close the paper.

Real capacity
Sites chosen from their AI Site Twin, on current capacity and performance, not on who a CRO already knows.
Template budgets
Budgets built against fair market value and ready to submit on day one.
Master agreements
Agreements held at the site level, plus national templates such as the NHS model CTA.
Scored partners
In-country regulatory and site activation partners, rated on real cycle time, quality and cost.
Ryght in Time

Just-in-time activation at sites that are already ready.

Ryght in Time is rapid site activation at sites in the Ryght Platinum network. Each member site has done three things before a study arrives.

Explore Ryght in Time
01
Joined the Platinum network
02
Connected its data systems
03
Agreed to pre-negotiated templates and agreements
Commercial model

You pay for startup work. Everything else passes through at cost.

We compete on the startup services fee. Ethics, lab, drug supply and filing fees pass through at zero markup. Our target is a startup cost per site 30% below the $20K to $40K a full-service CRO charges.

Ryght target
Who runs it
Stephanie Smith
VP of Clinical Operations
[Two-line bio from Stephanie]
Dr. Chadi Nabhan
Chief Medical Officer
Medical oncologist and hematologist
Country guides

Every country has its own rules. Ryght runs them all.

Last verified September 2026
United Kingdom
One combined MHRA and ethics review. One REC opinion covers every UK site. The NHS model CTA shortens contracts.
New regulations in force since 28 April 2026. Government target: 150 days to set up a commercial trial.
Read the UK guide
Australia
The ethics committee is the gate. The CTN is a notification to the TGA, and recruiting does not wait for its acknowledgement.
A named Australian sponsor is required. The Medicines Australia CTRA template shortens contracts.
Read the Australia guide
European Union
One CTIS application covers every member state in the trial. Ryght picks the reporting member state from Site Twin data.
The FAST-EU pilot targets 70 days or less from submission to decision for eligible multinational trials.
Read the EU guide
Questions

What sponsors ask first.

Is Ryght a CRO?

No. Ryght runs the startup layer. Screening sites hand off to your CRO or study conduct partner.

Can we use Ryght with our CRO?

Yes, but start with Ryght. Ryght identifies the best geographies and sites first, then helps you choose the right CRO for that footprint, if you need one. No CRO? Ryght partners with technology companies for monitoring and study management.

Who signs the contracts?

You do. Your team keeps negotiation limits, legal approval and final signature. Ryght drafts, checks and routes.

What if a site stalls?

Every site runs on one tracker with an owner and a date per step. A stalled site is escalated or replaced from the ranked list.

What does it cost?

A startup services fee per site. Pass-through costs stay at cost.

Send a synopsis. Get a site list and a startup plan.

We return a ranked site and country list in under 24 hours, with a startup timeline built for your protocol.

Plan your study startup Talk to our team